NIH has cleared a first-in-human safety study of mitragynine, the primary alkaloid in kratom, to assess whether this opioid-receptor compound could be developed as a treatment for opioid use disorder. The move reflects both the promise seen in preclinical research and the central concern that kratom is itself psychoactive and potentially addictive, making safety and tolerability the immediate question.